Actively Recruiting
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Led by Jemincare · Updated on 2024-07-09
80
Participants Needed
1
Research Sites
163 weeks
Total Duration
On this page
Sponsors
J
Jemincare
Lead Sponsor
Z
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
CONDITIONS
Official Title
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and willing to sign informed consent
- Male or female aged 18 years or older
- Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma
- At least one measurable lesion according to RECIST v1.1
- Life expectancy of at least 12 weeks
- Adequate organ function
You will not qualify if you...
- Known active central nervous system metastases or cancerous meningitis
- Received systemic anticancer monoclonal antibodies or immunosuppressants within 4 weeks before first dose
- Received chemotherapy, targeted therapy, or other investigational therapy within 2 weeks before first dose
- Not recovered from grade 2 or higher adverse event from prior anti-tumor treatment
- Impaired heart function or significant cerebrovascular or cardiovascular disease
- Dysphagia or known drug absorption disorders
- History of other malignancy within past 5 years
- Severe oncological complications
- Currently participating in other clinical studies
- Considered unsuitable for participation by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Caancer Hospital
Beijing, China
Actively Recruiting
Research Team
H
Huihui Xiang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here